{
 "page": "https://insights.moraph.com/regulators/dea-diversion",
 "publisher": "Moraph",
 "license": "https://creativecommons.org/licenses/by/4.0/",
 "license_note": "License: CC BY 4.0. Underlying government texts are public domain or under their own terms.",
 "attribution": "Moraph Insights, https://insights.moraph.com/regulators/dea-diversion",
 "slug": "dea-diversion",
 "name": "Drug Enforcement Administration, Diversion Control Division",
 "short_name": "DEA",
 "kind": "Federal agency",
 "sectors": [
  "Healthcare"
 ],
 "lens": "Regulation & Compliance",
 "url": "https://www.deadiversion.usdoj.gov/",
 "same_as": [
  "https://www.federalregister.gov/agencies/drug-enforcement-administration"
 ],
 "in_short": "DEA's Diversion Control Division registers practitioners and others who handle controlled substances under the Controlled Substances Act; a practitioner with practice locations in more than one state needs a separate DEA registration in each. Registrants must report a theft or significant loss within one business day of discovery, and DEA can move to suspend or revoke a registration through an Order to Show Cause or, where there is imminent danger to public health or safety, an Immediate Suspension Order. The fourth temporary extension of the COVID-19 telemedicine flexibilities lets registered practitioners prescribe schedule II to V controlled medications by telemedicine without a prior in-person evaluation through December 31, 2026, while DEA's special registration rule remains a proposal.",
 "remit": [
  {
   "text": "The Diversion Control Division's site takes online applications to obtain or renew a DEA registration and offers Ask REGIS, a chatbot released in beta, for general questions about DEA registration requirements and processes.",
   "source": "s1",
   "checked": "2026-11-14"
  },
  {
   "text": "Its home page notes that a waiver registration is no longer required to treat patients with opioid use disorder, and its registration menu links to the MATE Act training requirements.",
   "source": "s1",
   "checked": "2026-11-14"
  },
  {
   "text": "Under 21 U.S.C. 824(a) DEA may suspend or revoke a registration on findings that include material falsification of the application or an act that would make registration inconsistent with the public interest.",
   "source": "s2",
   "checked": "2026-11-14"
  }
 ],
 "supervises": [
  {
   "text": "Only persons actually engaged in handling controlled substances, such as dispensing, must hold a registration (21 CFR 1301.11(a)); a practitioner must also have authority under the laws of the state where it practices to dispense controlled substances.",
   "source": "s3",
   "checked": "2026-11-14"
  },
  {
   "text": "A practitioner with a professional practice location in more than one state must obtain a separate DEA registration in each of those states; a DEA registration based on a state license cannot authorize controlled substance dispensing outside that state.",
   "source": "s3",
   "checked": "2026-11-14"
  }
 ],
 "examines": [
  {
   "text": "A registrant must notify the DEA Field Division Office in its area, in writing, of any theft or significant loss of controlled substances within one business day of discovery, and file a complete DEA Form 106 within 45 days (21 CFR 1301.76(b)).",
   "source": "s4",
   "checked": "2026-11-14"
  },
  {
   "text": "Before denying, revoking or suspending a registration, DEA serves an Order to Show Cause; the registrant may submit a corrective action plan, which DEA reviews to decide whether to discontinue or defer the proceedings (21 U.S.C. 824(c)).",
   "source": "s2",
   "checked": "2026-11-14"
  }
 ],
 "guidance": [
  {
   "text": "DEA's telemedicine page says it is drafting updated regulations for telemedicine; it held public listening sessions on September 12 and 13, 2023, receiving comments from 58 practitioners, experts, advocates, patients and others.",
   "source": "s5",
   "checked": "2026-11-14"
  }
 ],
 "rules": [
  {
   "text": "Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (DEA with HHS, published December 31, 2025): effective January 1, 2026 through December 31, 2026, DEA-registered practitioners may prescribe schedule II to V controlled substances by telemedicine to a patient they have not evaluated in person, if the rule's conditions are met.",
   "source": "s6",
   "checked": "2026-11-14"
  },
  {
   "text": "The extension cites the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, with the telemedicine definition at 21 U.S.C. 802(54) and the in-person evaluation requirement at 21 U.S.C. 829(e).",
   "source": "s6",
   "checked": "2026-11-14"
  },
  {
   "text": "Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed January 17, 2025) would establish a special registration framework with three types of special registration and heightened prescription, recordkeeping and reporting requirements. Proposed, as checked on 2026-11-14.",
   "source": "s7",
   "checked": "2026-11-14"
  },
  {
   "text": "The final rules on buprenorphine treatment via telemedicine and on continuity of care via telemedicine for Veterans Affairs patients, first published January 17, 2025: the extension published December 31, 2025 states that they go into effect on December 31, 2025.",
   "source": "s6",
   "checked": "2026-11-14"
  }
 ],
 "enforcement": [
  {
   "text": "DEA calls Orders to Show Cause and Immediate Suspension Orders its administrative actions; it may issue them when it finds a registrant has violated the Controlled Substances Act.",
   "source": "s2",
   "checked": "2026-11-14"
  },
  {
   "text": "An Immediate Suspension Order under 21 U.S.C. 824(d) is used where there is imminent danger to public health or safety, meaning a substantial likelihood of an immediate threat of death, serious bodily harm or abuse of a controlled substance.",
   "source": "s2",
   "checked": "2026-11-14"
  },
  {
   "text": "The Division's What's New page posts Decision and Order documents in registrant cases, the latest dated November 12, 2026 as checked on 2026-11-14.",
   "source": "s8",
   "checked": "2026-11-14"
  }
 ],
 "channels": [
  {
   "label": "Registration",
   "url": "https://www.deadiversion.usdoj.gov/drugreg/registration.html",
   "checked": "2026-11-14"
  },
  {
   "label": "Telemedicine",
   "url": "https://www.deadiversion.usdoj.gov/Telemedicine.html",
   "checked": "2026-11-14"
  },
  {
   "label": "Administrative actions",
   "url": "https://www.deadiversion.usdoj.gov/administrative_actions.html",
   "checked": "2026-11-14"
  },
  {
   "label": "What's New (decisions, orders and rules)",
   "url": "https://www.deadiversion.usdoj.gov/new.html",
   "checked": "2026-11-14"
  }
 ],
 "sources": [
  {
   "id": "s1",
   "title": "DEA Diversion Control Division (home page)",
   "publisher": "Drug Enforcement Administration, Diversion Control Division",
   "url": "https://www.deadiversion.usdoj.gov/",
   "checked": "2026-11-14"
  },
  {
   "id": "s2",
   "title": "Administrative Actions",
   "publisher": "Drug Enforcement Administration, Diversion Control Division",
   "url": "https://www.deadiversion.usdoj.gov/administrative_actions.html",
   "checked": "2026-11-14"
  },
  {
   "id": "s3",
   "title": "Registration Q&A",
   "publisher": "Drug Enforcement Administration, Diversion Control Division",
   "url": "https://www.deadiversion.usdoj.gov/faq/registration-faq.html",
   "checked": "2026-11-14"
  },
  {
   "id": "s4",
   "title": "21 CFR 1301.76, Other security controls for practitioners (eCFR)",
   "publisher": "Office of the Federal Register (eCFR)",
   "url": "https://www.ecfr.gov/current/title-21/section-1301.76",
   "checked": "2026-11-14"
  },
  {
   "id": "s5",
   "title": "Telemedicine",
   "publisher": "Drug Enforcement Administration, Diversion Control Division",
   "url": "https://www.deadiversion.usdoj.gov/Telemedicine.html",
   "checked": "2026-11-14"
  },
  {
   "id": "s6",
   "title": "Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register document 2025-24123 (December 31, 2025; govinfo)",
   "publisher": "Drug Enforcement Administration and Department of Health and Human Services (Federal Register)",
   "url": "https://www.govinfo.gov/content/pkg/FR-2025-12-31/html/2025-24123.htm",
   "checked": "2026-11-14"
  },
  {
   "id": "s7",
   "title": "Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, document 2025-01099 (January 17, 2025; abstract opened through the Federal Register API)",
   "publisher": "Drug Enforcement Administration (Federal Register)",
   "url": "https://www.federalregister.gov/documents/2025/01/17/2025-01099/special-registrations-for-telemedicine-and-limited-state-telemedicine-registrations",
   "checked": "2026-11-14"
  },
  {
   "id": "s8",
   "title": "What's New",
   "publisher": "Drug Enforcement Administration, Diversion Control Division",
   "url": "https://www.deadiversion.usdoj.gov/new.html",
   "checked": "2026-11-14"
  }
 ],
 "published": "2026-11-14",
 "last_reviewed": "2026-11-14",
 "omitted": [
  {
   "where": "remit",
   "reason": "The Division's program description page returned HTTP 404 and dea.gov refused automated access on 2026-11-14, so no mission statement or registrant counts are given."
  },
  {
   "where": "rules",
   "reason": "No telemedicine rule after the December 31, 2025 extension was found in the Federal Register under RINs 1117-AB40 or 1117-AB78 as checked on 2026-11-14; what applies after December 31, 2026 is not stated."
  }
 ]
}
